16.43 USD
+0.49 (+3.07%)
At close: Feb 6, 2026
16.45 USD
+0.02 (+0.12%)
After Hours: 2/6/2026, 8:16:54 PM
Taking everything into account, ADMA scores 7 out of 10 in our fundamental rating. ADMA was compared to 523 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make ADMA suitable for growth investing!
1. Profitability
1.1 Basic Checks
- ADMA had positive earnings in the past year.
- ADMA had a positive operating cash flow in the past year.
- ADMA had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
- ADMA has a better Return On Assets (36.83%) than 98.86% of its industry peers.
- The Return On Equity of ADMA (48.57%) is better than 98.67% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 25.76%, ADMA belongs to the top of the industry, outperforming 98.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ADMA's Profit Margin of 42.87% is amongst the best of the industry. ADMA outperforms 98.10% of its industry peers.
- ADMA has a Operating Margin of 34.19%. This is amongst the best in the industry. ADMA outperforms 97.33% of its industry peers.
- With a decent Gross Margin value of 54.71%, ADMA is doing good in the industry, outperforming 76.76% of the companies in the same industry.
- ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
- ADMA has more shares outstanding than it did 1 year ago.
- ADMA has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
- ADMA has an Altman-Z score of 19.10. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
- ADMA has a Altman-Z score of 19.10. This is amongst the best in the industry. ADMA outperforms 88.95% of its industry peers.
- The Debt to FCF ratio of ADMA is 1.78, which is an excellent value as it means it would take ADMA, only 1.78 years of fcf income to pay off all of its debts.
- ADMA has a better Debt to FCF ratio (1.78) than 93.71% of its industry peers.
- ADMA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- ADMA has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: ADMA underperforms 64.19% of its industry peers.
- Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 19.1 |
ROIC/WACC2.91
WACC8.85%
2.3 Liquidity
- ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
- ADMA has a Current ratio of 7.13. This is in the better half of the industry: ADMA outperforms 70.86% of its industry peers.
- A Quick Ratio of 3.65 indicates that ADMA has no problem at all paying its short term obligations.
- ADMA has a Quick ratio of 3.65. This is comparable to the rest of the industry: ADMA outperforms 46.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.86%, which is quite impressive.
- Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 27.62%.
- The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
- ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.00% yearly.
- The Revenue is expected to grow by 21.50% on average over the next years. This is a very strong growth
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 30.43, the valuation of ADMA can be described as expensive.
- 93.14% of the companies in the same industry are more expensive than ADMA, based on the Price/Earnings ratio.
- ADMA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.93, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 18.00, ADMA is valued on the expensive side.
- 94.29% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
- ADMA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.43 | ||
| Fwd PE | 18 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.71% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, ADMA is valued cheaper than 91.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 96.29 | ||
| EV/EBITDA | 22.41 |
4.3 Compensation for Growth
- ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- ADMA has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as ADMA's earnings are expected to grow with 33.64% in the coming years.
PEG (NY)1.57
PEG (5Y)N/A
EPS Next 2Y35.12%
EPS Next 3Y33.64%
5. Dividend
5.1 Amount
- No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
16.43
+0.49 (+3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners93.5%
Inst Owner Change-3.36%
Ins Owners2.35%
Ins Owner Change-0.33%
Market Cap3.91B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (59.34%)
Short Float %8.13%
Short Ratio7.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.43 | ||
| Fwd PE | 18 | ||
| P/S | 8 | ||
| P/FCF | 96.29 | ||
| P/OCF | 60.18 | ||
| P/B | 9.07 | ||
| P/tB | 9.15 | ||
| EV/EBITDA | 22.41 |
EPS(TTM)0.54
EY3.29%
EPS(NY)0.91
Fwd EY5.56%
FCF(TTM)0.17
FCFY1.04%
OCF(TTM)0.27
OCFY1.66%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.57
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 19.1 |
F-Score7
WACC8.85%
ROIC/WACC2.91
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.